pehub.com -- Evolva SA, a Swiss biotech company that uses a genetic chemistry platform to developer small molecule drugs, has agreed to go public via a reverse merger with Arpida Ltd., which is listed on the Swiss stock exchange (SIX: ARPN). Evolva has raised around $20 million in VC funding from firms like Novartis Venture, Aravis, Sunstone Capital and Dansk Innovationsinvestering. It also says it plans to raise another CHF 25 million from new and existing investors.
